A DOUBLE-BLIND, PLACEBO CONTROLLED-STUDY OF GINKGO-BILOBA EXTRACT (TANAKAN) IN ELDERLY OUTPATIENTS WITH MILD TO MODERATE MEMORY IMPAIRMENT

被引:110
|
作者
RAI, GS [1 ]
SHOVLIN, C [1 ]
WESNES, KA [1 ]
机构
[1] COGNIT DRUG RES LTD,READING,ENGLAND
关键词
GINKGO BILOBA EXTRACT; GLYCOSIDES; TERPENES; PLANTS; MEDICINAL; MEMORY DISORDERS; AGED;
D O I
10.1185/03007999109111504
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Thirty-one patients over the age of 50 years and showing a mild to moderate degree of memory impairment entered a 6-month double-blind, placebo controlled, parallel group design study to assess the effects of a standardized Ginkgo biloba extract (containing 24% flavonoid glycosides and 6% terpenes) on cognitive function. Patients were allocated at random to receive oral doses of 40 mg Ginkgo biloba extract or identical placebo 3-times daily. Assessments were made at baseline and after 12 and 24 weeks of treatment using a range of psychometric tests. Efficacy data were available for 27 patients (15 in the placebo group and 12 in the active treatment group). Statistical analysis of the data as compared to baseline suggests that Ginkgo biloba extract had a beneficial effect on cognitive function in this group of patients. Performance on the Digit Copying sub-test of the Kendrick battery was significantly improved at both 12 and 24 weeks, while the median speed of response on a computerized version of a classification task also showed a significant superiority over placebo at 24 weeks.
引用
收藏
页码:350 / 355
页数:6
相关论文
共 50 条
  • [21] The use of Ginkgo biloba in Raynaud's disease: a double-blind placebo-controlled trial
    Muir, AH
    Robb, R
    McLaren, M
    Daly, F
    Belch, JJF
    VASCULAR MEDICINE, 2002, 7 (04) : 265 - 267
  • [22] A Double-Blind Placebo Controlled Trial of Ginkgo biloba Added to Risperidone in Patients with Autistic Disorders
    Hasanzadeh, Elmira
    Mohammadi, Mohammad-Reza
    Ghanizadeh, Ahmad
    Rezazadeh, Shams-Ali
    Tabrizi, Mina
    Rezaei, Farzin
    Akhondzadeh, Shahin
    CHILD PSYCHIATRY & HUMAN DEVELOPMENT, 2012, 43 (05) : 674 - 682
  • [23] CALCITONIN PROPHYLAXIS OF MIGRAINE - A DOUBLE-BLIND PLACEBO CONTROLLED-STUDY
    GENNARI, C
    FRANCINI, G
    GONNELLI, S
    MONTAGNANI, M
    JOURNAL OF BONE AND MINERAL RESEARCH, 1986, 1 (01) : 151 - 151
  • [24] A 26-week analysis of a double-blind, placebo-controlled trial of the Ginkgo biloba extract EGb 761® in dementia
    Le Bars, PL
    Kieser, M
    Itil, K
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2000, 11 (04) : 230 - 237
  • [25] FENOPROFEN IN THE PROPHYLAXIS OF MIGRAINE - A DOUBLE-BLIND, PLACEBO CONTROLLED-STUDY
    DIAMOND, S
    SOLOMON, GD
    FREITAG, FG
    MEHTA, ND
    HEADACHE, 1987, 27 (05): : 246 - 249
  • [26] DOUBLE-BLIND, PLACEBO CONTROLLED-STUDY OF NEDOCROMIL SODIUM IN ASTHMA
    ARMENIO, L
    BALDINI, G
    BARDARE, M
    BONER, A
    BURGIO, R
    CAVAGNI, G
    LAROSA, M
    MARCUCCI, F
    DELGIUDICE, MM
    PULEJO, MR
    RONCHETTI, R
    VERINI, M
    VIERUCCI, A
    VILLA, MP
    ARCHIVES OF DISEASE IN CHILDHOOD, 1993, 68 (02) : 193 - 197
  • [27] A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia
    Zhang, XY
    Zhou, DF
    Zhang, PY
    Wu, GY
    Su, JM
    Cao, LY
    JOURNAL OF CLINICAL PSYCHIATRY, 2001, 62 (11) : 878 - 883
  • [28] ONDANSETRON - A DOUBLE-BLIND PLACEBO CONTROLLED-STUDY IN ACUTE SCHIZOPHRENIA
    MCBAIN, SL
    DINEEN, M
    WELLER, M
    TAYLOR, S
    COOKSEY, P
    WILLIAMS, P
    CORN, T
    SCHIZOPHRENIA RESEARCH, 1992, 6 (02) : 112 - 112
  • [29] A DOUBLE-BLIND PLACEBO CONTROLLED-STUDY OF CINNARIZINE IN THE PROPHYLAXIS OF SEASICKNESS
    HARGREAVES, J
    PRACTITIONER, 1980, 224 (1343) : 547 - 550
  • [30] DOUBLE-BLIND CONTROLLED-STUDY OF CLOBAZAM FOR TREATMENT OF ANXIETY IN PSYCHIATRIC OUTPATIENTS
    CHARALAMPOUS, KD
    SERMAS, CE
    NEWSOM, WA
    KEEPERS, GA
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1977, 21 (06): : 779 - 785